Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) Debt to Equity (2016 - 2023)

Arcadia Biosciences' Debt to Equity history spans 10 years, with the latest figure at $0.0 for Q1 2023.

  • For Q1 2023, Debt to Equity fell 60.61% year-over-year to $0.0; the TTM value through Mar 2023 reached $0.0, down 60.61%, while the annual FY2022 figure was $0.0, 11.95% up from the prior year.
  • Debt to Equity reached $0.0 in Q1 2023 per RKDA's latest filing, down from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.21 in Q3 2020 to a low of $0.0 in Q1 2023.
  • Average Debt to Equity over 5 years is $0.04, with a median of $0.01 recorded in 2019.
  • Peak YoY movement for Debt to Equity: skyrocketed 14367.24% in 2020, then plummeted 98.68% in 2021.
  • A 5-year view of Debt to Equity shows it stood at $0.02 in 2019, then soared by 535.71% to $0.11 in 2020, then crashed by 98.17% to $0.0 in 2021, then rose by 11.95% to $0.0 in 2022, then tumbled by 60.87% to $0.0 in 2023.
  • Per Business Quant, the three most recent readings for RKDA's Debt to Equity are $0.0 (Q1 2023), $0.0 (Q4 2022), and $0.0 (Q3 2022).